Article info

Download PDFPDF
Abatacept is second to rituximab at risk of HBsAg reverse seroconversion in patients with rheumatic disease

Authors

  • Ming-Han Chen Division of Allergy, Immunology, & Rheumatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, TaiwanFaculty of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan PubMed articlesGoogle scholar articles
  • I-Cheng Lee Faculty of Medicine, National Yang Ming Chiao Tung University, Taipei, TaiwanDivision of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan PubMed articlesGoogle scholar articles
  • Ming-Huang Chen Faculty of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan PubMed articlesGoogle scholar articles
  • Ming-Chih Hou Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan PubMed articlesGoogle scholar articles
  • Chang-Youh Tsai Division of Allergy, Immunology, & Rheumatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, TaiwanFaculty of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan PubMed articlesGoogle scholar articles
  • Yi-Hsiang Huang Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, TaiwanInstitute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan PubMed articlesGoogle scholar articles
  1. Correspondence to Professor Yi-Hsiang Huang, Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan; yhhuang{at}vghtpe.gov.tw; Dr Ming-Han Chen, Division of Allergy, Immunology, & Rheumatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan; meikankimo{at}yahoo.com.tw
View Full Text

Citation

Chen M, Lee I, Chen M, et al
Abatacept is second to rituximab at risk of HBsAg reverse seroconversion in patients with rheumatic disease

Publication history

  • Received May 13, 2021
  • Accepted June 18, 2021
  • First published June 29, 2021.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.